瘤微环境触发的半导体聚合物纳米变换器的聚合,用于可自编程的正位体质瘤治疗药物
Zheming Song1, Li Li2, Anni Zhu1
1State Key Laboratory of Advanced Fiber Materials, College of Biological Science and Medical Engineering, Donghua University, Shanghai 201620, China.
Theranostics
|December 5, 2025
概括
这项研究引入了一种新的纳米变换器,该纳米变换器在瘤微环境中转化,以增强质瘤的诊断和治疗. 响应性纳米材料可以改善成像和治疗,并有可能促进对抗癌症的免疫反应.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 在瘤学瘤学.
背景情况:
- 纳米异构体为质瘤提供综合诊断和治疗,但在瘤微环境 (TME) 内的动态结构适应方面存在局限性.
- 目前的纳米异能材料在结构性可塑性方面扎,阻碍了在复杂的TME条件下获得最佳的异能效果.
研究的目的:
- 开发一种基于半导体聚合物 (SP) 的纳米变换器 (TM-P@SPN),能够进行聚合增强的,可自编程的光学,以响应TME.
- 通过多式成像和组合疗法,包括免疫疗法,研究纳米变换器改善质瘤管理的能力.
主要方法:
- 合成的TM-P@SPN使用SP作为核心功能组件,KLVFF链接的PEG作为触发开关,以及转移素修饰的二氧化 (TM) 作为准.
- 利用了TME中的谷氨 (GSH) 响应,诱导纳米变换器的分解和随后的疏水聚合.
- 评估了纳米变换器在光成像 (FLI),光声成像 (PAI),磁共振成像 (MRI),光热疗法 (PTT) 和化学动力疗法 (CDT) 的正管质瘤模型中的性能.
主要成果:
- GSH触发了TM-P@SPN分解,释放了Mn(II) 并使SP-KLVFF聚合成为可能,从而增强了PAI和PTT的疗效.
- 释放的Mn(II) 促进了T1加权的MRI和化学动力学治疗 (CDT).
- 结合CDT和PTT诱导免疫细胞死亡并激活STING通路,促进树突细胞成熟和全身免疫反应.
结论:
- 响应TME的纳米变换器成功地证明了质瘤的自我可编程治疗方法.
- 获得了增强的多式成像 (FLI增强的PAI-MRI) 和组合疗法 (CDT增强的PTT-免疫疗法).
- 开发的纳米变换器提供了一个有前途的策略,以克服目前纳米激素在质瘤管理中的局限性.
更多相关视频
10:49Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models
Published on: June 16, 2022
2.9K
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
3.0K
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
